High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
about
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualizationGemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Acute myeloid leukemia stem cells and CD33-targeted immunotherapyThe role of gemtuzumab ozogamicin in acute leukaemia therapy.Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Antibody-based therapy of leukaemia.Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.Investigational antibody-drug conjugates for hematological malignancies.Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Industrial natural product chemistry for drug discovery and development.Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemiaGemtuzumab ozogamicin in acute myeloid leukemia.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy.Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial.Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.
P2860
Q28476825-DBB90E13-7C3E-4A33-9403-BFC620D15896Q34172042-0F3DE306-E3ED-4509-AB29-0A6AB2E0BCFAQ35909648-224DFEC4-C705-421C-BC14-03A7D1D58CC1Q35980938-E0E698CB-0C96-4BD6-833B-2D422400E235Q36058588-2CE4AF25-1BAC-4202-8553-C25655B99FF5Q36367816-91C4033F-729E-4142-8770-815929FAAEB4Q36498399-63C940F0-3BB4-4937-8632-454AB0BF7DA4Q37311249-B335C7EE-CB25-436F-BDAD-4104336DD53FQ37512086-A4F9C1E8-A24B-4AD2-A67C-BD9E50D9E752Q37605247-3F0C3D2D-AD7B-4C2A-8C8E-2022C7C5C02BQ37818248-2CEEAD68-2EE4-451B-B6FD-9314E3E9C9B4Q37818256-B726095E-9827-4A27-A283-E5E3F2C9B868Q37910260-0F4A3D2C-7AC6-4ADA-A254-F239B8D37520Q38109541-8E6ABD81-5C7B-4AB1-B284-EB0AFEA8E0A7Q38154186-2BA61EBA-1AC9-436B-8814-F363BC3CE98EQ38662393-CC33E916-600C-47C6-93A9-AF5EF763B18AQ38701163-37B3F810-52F5-4CEF-BD52-E6E851C3C4B7Q38728718-13FBBAED-487B-40A8-A5C9-D010A5BDDD8AQ38987211-DDD87751-3C4C-477B-A1E4-CA9542D39D82Q39484177-4AA67BDC-6196-4309-BDFC-86BA8C7CECBCQ45123375-99FFF953-738C-4FAB-9FF6-AA2C18E894ECQ46236663-32C0FE00-8A46-4786-9DC7-1E2AEBA631E4Q53210874-8FD1BDAC-117E-4F9E-BE80-E87A25DAA6E7Q55354182-C08BA692-9AA2-4F2F-8BEA-CE389F11C8E4
P2860
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
High CD33-antigen loads in per ...... ute myeloid leukemia patients.
@en
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin
@nl
type
label
High CD33-antigen loads in per ...... ute myeloid leukemia patients.
@en
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin
@nl
prefLabel
High CD33-antigen loads in per ...... ute myeloid leukemia patients.
@en
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin
@nl
P2093
P2860
P356
P1433
P1476
High CD33-antigen loads in per ...... ute myeloid leukemia patients.
@en
P2093
J G te Marvelde
J J M van Dongen
M Boogaerts
P G Hoogeveen
V H J van der Velden
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403350
P577
2004-05-01T00:00:00Z